Background: Elevated D-dimer is known as predictor for severity of SARS-CoV2-infection. Increased D-dimer is associated with thromboembolic complications, but it is also a direct consequence of the acute lung injury seen in COVID-19 pneumonia. Objectives: To evaluate the rate of persistent elevated D-dimer and its association with thromboembolic complications and persistent ground glass opacities (GGO) after recovery from COVID-19. Methods: In this post hoc analysis of a prospective multicenter trial, patients underwent blood sampling, measurement of diffusion capacity, blood gas analysis, and multidetector computed tomography (MDCT) scan following COVID-19. In case of increased D-dimer (>0,5 μg/ml), an additional contrast medium-enhanced CT was performed in absence of contraindications. Results were compared between patients with persistent D-dimer elevation and patients with normal D-dimer level. Results: 129 patients (median age 48.8 years; range 19–91 years) underwent D-Dimer assessment after a median (IQR) of 94 days (64–130) following COVID-19. D-dimer elevation was found in 15% (19/129) and was significantly more common in patients who had experienced a severe SARS-CoV2 infection that had required hospitalisation compared to patients with mild disease (p = 0.049). Contrast-medium CT (n = 15) revealed an acute pulmonary embolism in one patient and CTEPH in another patient. A significant lower mean pO2 (p = 0.015) and AaDO2 (p = 0.043) were observed in patients with persistent D-Dimer elevation, but the rate of GGO were similar in both patient groups (p = 0.33). Conclusion: In 15% of the patients recovered from COVID-19, persistent D-dimer elevation was observed after a median of 3 months following COVID-19. These patients had experienced a more severe COVID and still presented more frequently a lower mean pO2 and AaDO2.
Elevated D-dimer is known as predictor for severity of SARS-CoV2-infection. Thereby, elevated D-dimer is associated with thromboembolic complications, but it is also a direct consequence of the acute lung injury seen in COVID-19 pneumonia. To evaluate the rate of persistent elevated D-dimer and its association with thromboembolic complications and persistent ground glass opacities (GGO) after recovery from COVID-19. In this post hoc analysis of a prospective multicenter trial, patients underwent blood sampling, measurement of diffusion capacity, blood gas analysis and multidetector computed tomography (MDCT) scan following COVID-19. In case of increased D-dimer (>0,5 µg/ml), an additional contrast medium-enhanced CT was performed in absence of contraindications. Results were compared between patients with persistent D-dimer elevation and patients with normal D-dimer. 129 patients (median age 48.8 years; range 19-91 years) underwent D-Dimer assessment after a median (IQR) of 94 days (64-130) following COVID-19. D-dimer elevation was found in 15% (19/129) and was significantly more common in patients who had experienced a severe SARS-CoV2 infection that had required hospitalisation compared to patients with mild disease (p=0.049). Contrast-medium CT (n=15) revealed an acute pulmonary embolism in one and CTEPH in another patient. A significant lower mean pO2 (p=0.015) and AaDO2 (p=0.043) were observed in patients with persistent D-Dimer elevation, but the rate of GGO were similar in both patient groups (p=0.33) In 15% of the patients recovered from COVID-19, persistent D-dimer elevation was observed after a median of 3 months following COVID-19. Those had a more severe COVID and still a lower mean pO2 and AaDO2.
Multiple studies report persistent symptoms following SARS-CoV-2 infection including fatigue, dyspnoea, headache, chest tightness and cough (e.g. Carfi, A. et al. JAMA 2020; 324(6):603-605). Frequency and prognosis of respiratory symptoms, limitations in lung function and persistent changes of lung parenchyma on high-resolution computed tomography (HRCT) following SARS-CoV-2 infection remain unclear. The objective of this study is to determine whether patients develop structural lung disease after recovery from COVID-19. We conduct an ongoing multicentric prospective study assessing patients after confirmed COVID-19. Patients undergo lung function tests and low-dose HRCT at baseline and after 3, 6 and 12 months. In this preliminary analysis, 158 patients aged 47.4 ± 15.8 years (range, 19-91 years) were identified. 44 patients were previously hospitalized. The median hospitalization was 11 days (range, 1-61 days). 65.9% of hospitalized patients (n=29) required oxygen therapy and 11.4% (n=5) required intensive care treatment. Lung function was assessed 17-291 days after confirmed COVID-19 with a median of 82 days. 15.8% of patients showed a reduced FVC < 80% and an impairment in TLC (TLC < lower limit of normal) could be detected in 8.3% of the cases. 40.9% of patients showed a reduction in diffusion capacity (TLCO) and in 13% the transfer coefficient (TLCO/VA) was reduced. Typical CT sings of COVID-19 pneumonia were observed in 32.7% of patients 9-303 days after confirmed COVID-19 with a median of 82 days. In a sample of 158 patients with confirmed COVID-19, one third showed persistent changes on HRCT and a reduction in diffusion capacity approximately 3 months after disease onset.
Background: Systemic autoimmune rheumatic diseases-associated interstitial lung disease (SARD-ILD) presents with varied disease courses, emphasizing the need for reliable predictors of progression. The prognostic utility of bronchoalveolar lavage (BAL) in SARD-ILD remains underexplored. The objective of this study was to evaluate the role of BAL fluid lymphocyte count in predicting disease progression in patients with SARD-ILD. Methods: This observational study included patients with SARD-ILD undergoing BAL as part of their diagnostic workup. Disease progression was defined as either Forced vital capacity (FVC) decrease >10%, two out of the following three criteria within two years: FVC decrease of 5–10%, worsening symptoms, increased fibrosis on imaging, or any of the following: escalation of treatment, Interstitial lung disease (ILD) exacerbation, lung transplantation, or disease-specific mortality. Logistic regression identified predictors of progression. Time-to-progression was assessed using Kaplan–Meier survival curves. The optimal BAL lymphocyte threshold for predicting progression was identified using the Youden Index and the Wilcoxon method. Results: We identified 89 patients, of whom 30 (33.7%) had progressive disease. Progressors had a significantly higher BAL lymphocyte count compared to non-progressors (31.6 ± 24.8% vs. 14.3 ± 16.5%, p < 0.001). BAL lymphocyte proportion was significantly and independently associated with disease progression (odds ratio, 1.05; 95% confidence interval 1.02–1.07; p < 0.01). A lymphocyte count above 9 percent was associated with a markedly increased risk of disease progression (odds ratio, 13.14; 95% confidence interval, 4.20–51.98; p < 0.01). Conclusions: BAL lymphocyte count was associated with a higher likelihood of progression in SARD-ILD. BAL assessment may help identify patients at increased risk of disease progression. However, these findings should be considered exploratory and require validation in larger prospective studies and across individual SARD-ILD subtypes.